🎉 Congratulations! If you've got this POAP, you’re officially in the exclusive club of folks who are ready to break free from the Bayer CloudTech UserGroup email chain! 🥳 Time to wave goodbye to those inbox notifications! ✌️💌

Cheers to our global gang! 🌍🌟 As the year draws to a close, we're giving a shoutout to the 13,000 amazing contributors on our platform. By leveraging Byron, the exchange within our company becomes more seamless, paving the way for new projects and strengthening our unity within Bayer. 🚀 Presenting this exclusive POAP as a massive thank you, because without you, this platform wouldn't be what it is. 🙌 Byron, an acronym for Bayer Open Network, is our Skills database for Bayer employees, including speed networking. We kicked off in 2018 as a True North grassroots side initiative, going live in 2020. Created by over 40 students and programming enthusiasts with the help of EY Croatia. Today, we have 13,000 registered users from 89 countries, in 293 cities. People have searched for something in Byron at least 25,000 times and engaged in 31,000 1:1 Speed network meetings. http://go/byron Looking ahead, we're thrilled about the future and the prospect of our community growing even larger. Can't wait for more collaborations and successes together in the coming year! 🎉✨ Art created by Lena Schermer

The Bayer Pharma Data Science & Artificial Intelligence (DS&AI) F2F meeting in Madrid was a great event! The motto Connect, Clarify & Commit came to life as we connected during networking sessions, breakout sessions and social events. At the poster session we learned about our progress embedding a product mindset and driving operational excellence, closely collaborating with our partners across R&D. We heard presentations, took part in discussions, unconference sessions, asked questions and shared ideas, setting foundations for the growth of DS&AI beyond 2023. The use of POAPs was a definite social success and I am sure you did not miss Jesús’ enthusiasm as he gave an overview of this new tool. By promoting its use, we drive new ways of using this sustainable and effective tool, ultimately helping to innovate its use by doctors, within clinical trials, for patients and more. There were fun elements as well, like the final night, where our very own flash-mob took to the dance floor and we danced until way past midnight! All this was made possible by the org team: Anke Ebert, Larsen Schnadhorst, Kathleen Thies, Sheila Elz, Stefanie Holt-Noreiks and Claudia Vogt. They have done an excellent job coordinating the event, with the perfect balance of presentations, speakers, entertainment, and networking. Now let us make sure we continue to further the impact we have on bringing innovative medicines to our patients. Sai Jasti, Head of DS&AI https://bayer.com/poap

Thanks for for taking the time to complete this survey, It was a pleasure seeing you in Madrid!

I've met Miriam during a DS&AI meeting in May 2023 in Madrid. She works as a Data Steward within Data Strategy and Governance in the group Proprietary Information Management. She is a (computational) chemist by training and has particular experience with our chemical labjournal data.

Our vision at Data Science Services & Solutions, DS3, is to Enable, Scale, and Operationalize R&D Data Science & AI capabilities to achieve Clinical Research and Development Speed, Efficiency, and Optimization. Learn more about our areas of responsibility, capabilities, strategic priorities, and collaborations. For more information, contact DS3 Head: Abi Velurethu. Artwork created using Stable Diffusion.

Given the considerable amount of data that is collected throughout clinical trials, it can be asked if this data can be used to improve our understanding of the trial, regardless of outcome. The radiomics pilot seeks to provide a toolkit that is capable of analyzing the different modalities of information found in clinical trials (genome, gene expression, biomarker, clinical information, and imaging information) to derive insights into why a patient may be responding, or why a clinical trial was unsuccessful. The current efforts have focused on clinical trials in oncology, while collaborating with the RED-ONC function. Overall, the project is in its pilot state, and demonstrating a proof of concept, while documenting many challenges and learnings with the development of such a toolkit. Potential directions that could expand this toolbox include deriving the factors that best predict why a patient would stay in a clinical trial, and providing assistance with patient selection of clinical trials. Other potential directions involve suggesting why a particular trial may have been unsuccessful and providing that information back to the drug development team.

With the new head of R&D Community Engagement, RDCE, a new set-up has also been introduced, which newly regulates the tasks and responsibilities of the business partners assigned to the functions, SPOCs, which stands for Single Point of Contact. What is now in scope and what is not? The poster provides information on this.